Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine

Britt W. H. Van Der Arend, Nancy Van Veelen, Joëlle E. T. De Ruijter, Michael H. Olsen, Antoinette MaassenVanDenBrink, Gisela M. Terwindt

Open source

DOI
10.3389/fneur.2024.1387044
Published
2024-04-29
Container
Frontiers in Neurology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fneur.2024.1387044,
  title = {Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine},
  author = {Britt W. H. Van Der Arend and Nancy Van Veelen and Joëlle E. T. De Ruijter and Michael H. Olsen and Antoinette MaassenVanDenBrink and Gisela M. Terwindt},
  year = {2024},
  journal = {Frontiers in Neurology},
  doi = {10.3389/fneur.2024.1387044},
  url = {https://doi.org/10.3389/fneur.2024.1387044}
}

RIS

TY  - JOUR
TI  - Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine
AU  - Britt W. H. Van Der Arend
AU  - Nancy Van Veelen
AU  - Joëlle E. T. De Ruijter
AU  - Michael H. Olsen
AU  - Antoinette MaassenVanDenBrink
AU  - Gisela M. Terwindt
PY  - 2024
JO  - Frontiers in Neurology
DO  - 10.3389/fneur.2024.1387044
UR  - https://doi.org/10.3389/fneur.2024.1387044
ER  - 

APA

Arend, B. W. H. V. D., Veelen, N. V., Ruijter, J. E. T. D., Olsen, M. H., MaassenVanDenBrink, A., & Terwindt, G. M. (2024). Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine. Frontiers in Neurology. https://doi.org/10.3389/fneur.2024.1387044

Source records